Mini Review

Bleeding complications at the access sites during catheter directed thrombolysis for acute limb ischaemia: Mini review

Elias Noory*, Tanja Böhme, Ulrich Beschorner and Thomas Zeller

Clinic for Cardiology and Angiology II, University Heart Centre, Freiburg- Bad Krozingen, Germany

Abstract

Acute and subacute ischemia of the lower limbs represents a major emergency with a high in-hospital mortality, complication, and leg amputation rates.

Treatment options for acute limb ischemia include systemic anticoagulation, followed by various catheter based options including infusion of fibrinolytic agents (pharmacological thrombolysis), pharmacomechanical thrombolysis, catheter-mediated thrombus aspiration, mechanical thrombectomy, and any combination of the above or open surgical intervention (thromboembolectomy or surgical bypass).

Minor and major bleeding complication during catheter directed thrombolysis (CDT) especially at access site are frequent. Bleeding complications require often an interruption or termination of CDT affecting clinical outcome of the patients. Recently we examined a new access site bleeding protection device during CDT.

Catheter directed thrombolysis or surgery

Acute lower limb ischemia is caused by a reduction of arterial perfusion to the limb due to either embolic occlusion or local thrombosis. To date no clear therapy recommendations exist.

Three randomized, multicentre trials were published comparing thrombolysis with surgery: the Rochester study [1], the Surgery versus Thrombolysis for Ischemic Lower Extremity (STILE) trial, [2] and the Thrombolysis Or Peripheral Arterial Surgery (TOPAS) trial [3]. The consensus that emerged from these studies and others was that CDT should be considered as first-line treatment for acute limb ischemia under the following conditions: (1) symptoms of limb ischemia present for < 14 days, (2) no absolute contraindications to thrombolysis, and (3) the predicted time to re-establish antegrade flow is short enough to preserve limb viability. Barring contraindications, CDT is indicated urgently for patients with marginal limb threat (category IIa according to the TASC criteria). Patients with immediate limb threat (category IIb) often require emergent operation as thrombolysis alone will not re-establish perfusion quickly enough to salvage the limb. Nonetheless, surgery incurs the risk of systemic effects of rapid reperfusion with compromise of cardiac, pulmonary, and renal functions that may result in prolonged hospitalization or even death [4,5]. If the cardiovascular risks of general anaesthesia due to comorbid disease and status of the affected limb outweigh the risk of a delay in reperfusion, then thrombolysis may be the best option. Last resort specialised interventional procedures and primary amputation is the only option permitting survival for patients with irreversible ischemia (category III). High perioperative mortality is associated with this degree of acute ischemia.

CDT and access site bleeding complications

Catheter-directed thrombolysis (CDT) is an attractive non-surgical option for many patients with acute critical ischemia, which involves the insertion of an infusion catheter (via the femoral artery) in the catheterization laboratory to reach the thrombus to allow the delivery of the pharmacological thrombolytic agent. Either an antegrade (in the direction of the blood flow) femoral artery puncture, or a retrograde route from the contralateral femoral artery can be used. Both bolus and continuous thrombolytic therapy may be performed. A variety of agents can be used in either low or high dose regimens. Urokinase and (recombinant) tissue plasminogen
Activator (rtPA) are the most effective agents, but neither of these have been shown to be superior in terms of efficacy and bleeding complications [6]. Following catheter insertion, the patient undergoing CDT is usually transferred to an intermediate or intensive care unit, with the delivery catheter in place, and the infusion running for up to 48 hours. Ebben undertook a review of studies comprising a total number of 10,643 cases of which 9877 received CDT for lower extremity arterial occlusion, with a mean treatment duration of 21.4 h and a freedom from amputation rate of 91%. Pooled results showed a thrombolysis duration with high dose protocols of 21.9 h, and 32.7 h with low dose protocols [7].

The major complications reported with CDT include major bleeding, and early termination of the CDT due to access site bleeding. Bleeding complications remain an important risk of CDT with bleeding rates in 18% (95% CI 17.8-18.3) of patients with bleeding rates of high dose protocols 16.7% (95% CI 16.3-17.1) and in low dose protocols of 13.4% (95% CI 12.8-14.0). Three factors associated with the bleeding risk are identified: the arterial puncture, the length of the CDT infusion with the sheath remaining in the femoral artery, and the thrombolytic agents leaking into the circulation, and having a systemic effect [8].

Abandonment or interruption rate of the CDT procedure can occur if complications are observed. Rates of interrupted CDT procedures due to bleeding range from 5% to 11.5% [9-11]. Definitive control of the access site remains an ongoing problem [12].

**Protection devices for reduction of access site bleeding complications during CDT**

Currently, there are no devices on the market that are approved and indicated for vascular access site bleeding protection during CDT in patients diagnosed with acute critical limb ischemia. CaveoMed developed the CaveoVasc® Thrombolysis Protection System, a vascular access protection device for use in thrombolysis procedures. Its function is to facilitate sheath access, and minimize risks of access site bleeding complications during lengthy catheter-directed thrombolysis procedures. Pressure balloons inflated outside the artery maintain a tight seal of the arterial puncture site throughout thrombolysis. After removing the thrombolysis catheter the protection sheath is removed, and hemostasis at the access site is managed as per the hospital’s standard procedure with a closure device or other techniques. A schematic representation of the use of the CaveoVasc® Thrombolysis Protection System is given in figure 1. An angiogram after placement of the CaveoVasc® Thrombolysis Protection System is shown in figure 2. The device got CE Mark June 2020.

Essentially, the system is intended to protect the patient from peri-procedural bleeding at the arterial access site, which currently remains a major problem for patients with critical limb ischemia undergoing CDT treatment. Recently we published the results from the first in men study demonstrating that the bleeding protection device lowered the rate of major bleeding events at puncture sites [13].

**Conclusion**

Catheter-directed thrombolysis (CDT) is an attractive non-surgical option for many patients with acute limb ischaemia. Bleeding complication especially at the access site remains a major unsolved problem, reducing procedural success rates
and contributing considerably to periprocedural mortality and morbidity.

Successful maintaining femoral access for long periods, up to as long as 40 hours, is still a challenge, especially in patients being treated with anticoagulation and thrombolytic drugs. Definitive control of the access site remains an ongoing problem.

The CaveoVasc® Thrombolysis Protection System can be used as add-on to current thrombolysis therapy. It has demonstrated a reduction of bleeding complications in CDT by protecting the puncture site by stabilizing the sheath with the double balloon technique and tamponing minor bleeding in the puncture channel. The application is simple and requires only a few additional intervention steps.

References